Healius Limited (ASX:HLS) announced it had completed the comprehensive review of its structure and assets announced on 5 March 2024.There view considered a range of alternatives,with the key objectives of maximising value for Healius? shareholders, both in the near term and in the future,whilst at the same ensuring a sustainable capital structure supportive of investment and ongoing growth in Healius? operations.

As a result of the review, Healius has commenced a formal process to explore options for the sale of its diagnostic imaging division, Lumus Imaging. Healius has appointed UBS Securities Australia Limited to assist with this exercise. Managing Director and CEO of Healius Paul Anderson said:?Lumus Imaging has a strong market position as one of Australia?s largest diagnostic imaging providers.

Recent investment and strategic initiatives at Lumus are delivering strong growth in revenue and profitability.?Realising value from Lumus will enable Healius to drive the earnings recovery in the company?s large-scale national pathology network and maximise growth in our clinical trials business, Agilex. Focusing on these businesses will reduce complexity and allow Healius to simplify our corporate cost base without impacting the quality of our services.?Healius intends to provide further detail on its strategic initiatives with respect to pathology and Agilex alongside its FY24 results in August.